Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
- Introduction (0:00)
- Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
- Practical Considerations with Oral SERDs (15:43)
- Potential Role of Combination Approaches with Oral SERDs (26:33)
- Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)
- Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)
- Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)
- Emerging Utility of Adjuvant Oral SERDs (1:10:20)
- Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)
